HOME >> BIOLOGY >> NEWS
The future of HIV therapeutics is brightening, according to Gladstone Institutes Director

Recent discoveries about the way that HIV infects cells are propelling the development of a broad spectrum of promising new antiviral drugs, according to an invited commentary on the topic in the current issue of Nature Immunology (August 27, 2004).

The assessment is made by Gladstone Institute of Virology and Immunology (GIVI) Director Warner Greene, MD, PhD, who also serves as professor of medicine, microbiology and immunology at the University of California, San Francisco.

In the piece, Greene points out that basic research on HIV, a relatively simple pathogen with only nine genes encoding 15 proteins, are leading to compelling new therapies that deny the initial entry of HIV into its cellular host. In addition, fast-moving research of naturally occurring factors with potent antiviral properties is opening the way for future development of an entirely new class of anti-HIV drugs.

New agents that block the first step in HIV's life cycle, the entry of the HIV virion (a single virus particle) into host CD4 T-cells, are quickly moving down the drug development pipeline. Chief among these therapeutics are drugs known as chemokine receptor antagonists that interfere with HIV's ability to bind to CCR5, one of two key surface receptors needed for the virus to penetrate the cell. Although these HIV co-receptors were identified only seven years ago, basic studies performed by both GIVI investigators and scientists around the world have helped accelerate clinical development of CCR5 antagonists as a new class of anti-HIV drugs. Several major pharmaceutical companies are now racing to the finishing line.

These advances address but one of the three steps required for successful entry of the HIV virus. The other two steps involve the attachment of HIV virions to surface CD4 receptors and the final fusion of virions to target cells. These steps are also being targeted with new antiviral drugs. Combinations of inhibitors acting at each o
'"/>

Contact: John Watson
jwatson@gladstone.ucsf.edu
415-695-3833
University of California - San Francisco
27-Aug-2004


Page: 1 2 3

Related biology news :

1. New fruitfly model of diabetes has future implications for pancreatic cell transplantation
2. Charting the future in prostate cancer care: A call to action
3. Sandia experiments may reduce possibility of future water wars
4. Will a reduction in military spending improve our environmental future?
5. Engineering endurance: The future of the Olympics?
6. The future of nanotechnology
7. Chemoradioimmunotherapy for advanced breast cancer: hope for the future?
8. Endometriosis: Could angiostatic therapy be the new treatment of the future?
9. Plants for the future: A European vision for plant biotechnology towards 2025
10. Plant pathologists to discuss the future of organic farming
11. Stem cells commit to a future of fat with one signal

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):
(Date:4/28/2017)... ... 2017 , ... Cynvenio Biosystems, Inc. a leader in personalized medicine ... monitoring (NEAT) study in partnership with Allentown, PA-based TME Research . The multi-center ... monitored over two years with Cynvenio’s ClearID Breast Cancer blood test. The study goal ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... digital pathology, today announced their digital pathology technology has the potential to eliminate ... five medical centers in The Netherlands as part of the 2017 ISBI ...
(Date:4/27/2017)... ... April 27, 2017 , ... Sierra Instruments ... on capillary thermal mass flow technology provide exponentially more accurate mass flow data ... 80% of all industrial processes—such as those involving chemical reactions, combustion, respiration, pharmaceutical, ...
(Date:4/27/2017)... 2017  Kinexum, a distinguished resource for research, development ... appointment of Thomas C. Seoh as President ... Kinexum founder, who becomes Executive Chairman and will continue ... Thomas Seoh commented, "I am ... and lead the firm,s remarkable team of life science ...
Breaking Biology Technology:
Cached News: